GSK to produce 1bn doses of Covid-19 vaccine booster next year
Published By : Prameya News Bureau | May 28, 2020 IST
Share
London, May 28: Pharmaceutical giant GlaxoSmithKline on Thursday said it plans to produce 1 billion doses of coronavirus vaccine adjuvant, an ingredient that makes vaccines work better, in 2021 to support multiple Covid-19 vaccine collaborations. Saying that it has started manufacture of the adjuvant at risk, the company added that it was in discussions with governments and global institutions about funding for production and supply of the adjuvant. "We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so," Roger Connor, President, GSK Global Vaccines, said in a statement. "We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple Covid-19 vaccines. "With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19," Connor added. GSK has formed several collaborations, including with scientific partners in North America, Europe and China, to develop vaccines, the company said, adding that discussions with potential partners on further collaborations are ongoing. In the last flu pandemic, GSK's pandemic adjuvant showed ability to reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people. Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections. GSK has prioritised its efforts towards making its pandemic adjuvant technology available to partners developing promising Covid-19 vaccine candidates that are suitable for use with an adjuvant. Confirmation of the enhanced manufacturing capacity follows completion of a review conducted across the company's global supply network. GSK said it will manufacture, fill and finish adjuvant for use in Covid-19 vaccines at sites in the UK, US, Canada and Europe.(IANS)
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
Know strategies to overcome social anxiety
SUM Hospital conducts Odisha’s first haploidentical hematopoitic stem transplantation
The silent storm: How stress wreaks havoc on your body
More than 5 grams of artificial sweetener saccharin a day can be fatal: Doctors
Low vision clinic inaugurated at AIIMS Bhubaneswar
Loneliness can cause an extreme desire for sugary foods: Study
Experts urge parents to wean children off social media
HK, Singapore food regulators red flag ‘cancer-causing’ ingredient in certain MDH, Everest spices
SUP’ORT training program for physiotherapists held at SUMUM
Patient awareness and interaction programme marks World Liver Day at AIIMS Bhubaneswar
Rising cases of pediatric liver issues linked to junk food epidemic
Vital organ, vital importance: Why maintaining liver health matters
World Liver Day 2024: These factors contribute to liver damage
Nestle baby food sugar study causes concern in India, Nestle India's shares fall
World Voice Day observed at SUM Phulnakhara Campus
Cadaveric kidney transplant performed at SCB Hospital
Closure of regn counter sparks tension at Bhubaneswar AIIMS
From pain to comfort: Discover the doctor who cares for your bad back
Boys born to mothers with HIV more vulnerable to death in infancy
World Hemophilia Day: Solidarity for people living with rare genetic disorder